Ascletis Pharma Inc. (01672.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.8x

Market Cap

HKD 9.81B

MomentumView details →

1D Return

−2.32%

YTD Return

−11.41%

RSI (14)

50.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.8x

Market Cap

HKD 9.81B

RSI (14)

50.4

MomentumView details →

1D Return

−2.32%

YTD Return

−11.41%

ProfitabilityView details →

Gross Margin

−221.10%

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−37.46%

ROA (TTM)

−34.70%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−95.43%

EPS YoY

−84.06%

FCF YoY

+27.88%

Revenue CAGR 3Y

−66.53%

EPS CAGR 3Y

−23.33%

EBITDA YoY

−57.74%

EarningsView details →

EPS (Actual)

−HKD 0.35

EPS Surprise

−53.70%

Beats (12Q)

0/12

Next Q EPS Est

−HKD 0.17

Avg Surprise (4Q)

−53.70%

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

12.92x

Quick Ratio

12.91x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

3.31M

Net Income (TTM)

−850.52M

Op. CF (TTM)

—

Next earningsMar 30, 2027 →

Latest newsMore news →

Shanghai Stock Exchange announced adjustments to the Stock Connect southbound eligible securities, adding 54 stocks including Baidu and Ascletis Pharma, and removing 15 stocks including Youjia Innovation.6h ago

Ascletis Pharma reported its interim results for the six months ended June 30, 2026, with revenue declining 48.9% year-on-year to 52.98 million RMB and net loss widening to 320 million RMB from 87.95 million RMB in the prior-year period.4d ago

Similar companies

Kymera Therapeutics, Inc.KYMR Nuvalent, Inc.NUVL Praxis Precision Medicines, Inc.PRAX Ionis Pharmaceuticals, Inc.IONS Abivax S.A.ABVX GenFleet Therapeutics (Shanghai) Inc.02595.HK Find similar companies →

Latest newsMore news →

Shanghai Stock Exchange announced adjustments to the Stock Connect southbound eligible securities, adding 54 stocks including Baidu and Ascletis Pharma, and removing 15 stocks including Youjia Innovation.6h ago Ascletis Pharma reported its interim results for the six months ended June 30, 2026, with revenue declining 48.9% year-on-year to 52.98 million RMB and net loss widening to 320 million RMB from 87.95 million RMB in the prior-year period.4d ago Ascletis announced that the first patient has been dosed in the global Phase III clinical program for ASC30, a once-daily oral small-molecule GLP-1 receptor agonist for chronic weight management.5d ago